Finally, there is preclinical data to support AR activation as a therapeutic strategy for ER + breast cancer, including ET and CDK4/6 inhibitor resistant ER + breast cancer models (Hickey et al., 2021). This evidence concerns the gene CDK4 and breast carcinoma.